You’re studying the online version of STAT Well being Tech, our information to how tech is reworking the life sciences. Signal as much as get this text delivered in your inbox each Tuesday and Thursday.
Telehealth abortion suppliers anticipate an uptick
Clinics prescribing abortion treatment on-line expect a surge if the Supreme Court docket repeals Roe v. Wade, as a leaked draft opinion launched this week suggests it’s going to. These clinics would solely have the ability to function in states the place abortion — and telemedicine prescription for the treatment — stays authorized. Meaning sufferers in additional restrictive states should cross state traces to entry digital care.
commercial
Although mainstream direct-to-consumer telehealth corporations centered on reproductive care like Nurx don’t prescribe abortion tablets, a handful of smaller suppliers like Hey Jane and Choix will after a digital session. And the tablets can now be mailed to sufferers as a substitute of largely solely being disbursed at brick-and-mortar clinics, following a latest regulatory change.
“Individuals listening to that Roe v Wade is overturned, lots of people will assume abortion is prohibited on this nation,” stated Cindy Adam, a nurse practitioner and CEO of Choix, which affords telemedicine abortion providers. “We get calls on daily basis asking, ‘Are the providers actual?” Our colleague Olivia Goldhill has more.
commercial
Cerebral dials again ADHD care amid reported federal investigation
On-line psychological well being care supplier Cerebral introduced Wednesday it was winding down its ADHD care, which incorporates nearly prescribing and delivering managed substances like Adderall. The information adopted the Wall Street Journal’s report earlier this week that on-line pharmacy Truepill was suspending success of sure managed substances like Adderall from companions together with Cerebral. Now, the Drug Enforcement Administration is reportedly investigating the corporate for points with supplier licensing and duplicate affected person accounts, Business Insider reports.
They’re the most recent in a string of excessive profile setbacks for telehealth suppliers that supply on-line prescribing and drug supply, and level to bigger questions on balancing telehealth’s advantages with the potential for abuse, experts told Mohana.
Tremendous Collection B investments of the week
Curebase, considered one of many new corporations profiting from new enthusiasm for innovation in scientific trials, introduced it had raised a $40 million Collection B spherical led by Business Ventures. Tom Lemberg, the corporate’s founder and CEO, informed STAT that Curebase will use the funds to construct out its providers to make them extra engaging to pharma companions, together with its new strategic investor Gilead Sciences.
Curebase has grow to be one of many go-to suppliers utilized by digital well being corporations hoping to provide proof to help FDA submissions and price effectiveness analysis, together with work with Blue Notice Therapeutics on remedies for cancer-related misery, AppliedVR’s persistent ache therapeutics, and metaMe, whose IBS remedy resulted in Curebase’s first FDA clearance. Curebase additionally has a take care of the Digital Therapeutics Alliance to assist develop a forthcoming paper on finest practices for scientific trials within the house.
In the meantime, Sidekick Well being, which makes digital therapeutics that assist handle persistent circumstances, introduced a $55 million Collection B spherical led by Novator Ventures. Sidekick has largely centered on software program used alongside pharma merchandise, together with collaborations with Pfizer, Bayer, and Lilly.
The place many early stage digital therapeutics companies have struggled with enterprise fashions, Sidekick co-founder and CEO Tryggvi Thorgeirsson stated the corporate has benefitted from hitching its stability sheet to pharma offers. “That is actually simply us studying the market dynamics,” he stated. “In 5 years, it’s going to be prescription digital therapeutics, largely with payer reimbursement, and that’s going to be the primary income. We’re simply not there but.”
Talking of DTx and pharma offers
Biogen introduced it might pay MedRhythms $3 million up entrance as the businesses comply with develop and commercialize an investigational digital therapeutic which makes use of music and software program to focus on strolling issues in individuals with a number of sclerosis. The deal could possibly be value north of $100 million plus royalties to MedRhythms, relying on assembly improvement milestones.
Talkspace persists
Talkspace on Tuesday reported its Q1 outcomes, which confirmed, effectively, not very a lot past with the ability to to chop advert spending with out completely annihilating its direct-to-consumer enterprise. Regardless of some seemingly constructive updates on longer-term initiatives meant to get the corporate on observe, the numbers don’t present a lot motion.
For those who haven’t been following alongside at house — and why wouldn’t you be? — Talkspace is within the midst of a messy, plodding transition because it seeks to concurrently rent a brand new C-suite whereas shifting its historically direct-to-consumer enterprise towards extra enterprise and well being plan gross sales. Analysts had been blended on how that progress goes, with Cowen seeing trigger for optimism within the firm’s cash-focused self-discipline and SVB Securities sustaining a skeptical outlook in the course of the firm’s turnaround efforts.
One level from the investor name value contemplating: As Talkspace tries to stabilize the enterprise and protect money, new rivals are cropping up and current rivals are elevating (and spending) big sums to gas progress. Even when there’s an crucial to indicate progress towards profitability, is Talkspace taking part in to win? Or to outlive?
Who is that this unnamed buyer?
Rockley Photonics introduced “it has shipped its VitalSpex Professional know-how for the non-invasive measurement of alcohol, glucose, and lactate to an early-access, tier-1 client wearables buyer.” Apple is by far the corporate’s most vital consumer, so the information might augur good issues for the long-rumored Apple Watch with glucose measuring capabilities.
What we’re studying
- Larger-ups knew about PillPack’s overbilling and over allotting insulin however dismissed considerations, Axios
- A knowledge dealer is promoting location knowledge for individuals who go to abortion clinics, Motherboard
- Congress strikes towards reforming FDA accelerated approvals, however with pharma-friendly concessions, STAT